Michael J. Tomsicek
2017 - ABIOMED
In 2017, Michael J. Tomsicek earned a total compensation of $2.2M as Vice President, Chief Financial Officer and Treasurer at ABIOMED, a 26% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $216,300 |
|---|---|
| Option Awards | $201,789 |
| Salary | $360,500 |
| Stock Awards | $1,399,470 |
| Total | $2,178,059 |
Tomsicek received $1.4M in stock awards, accounting for 64% of the total pay in 2017.
Tomsicek also received $216.3K in non-equity incentive plan, $201.8K in option awards and $360.5K in salary.
Rankings
In 2017, Michael J. Tomsicek's compensation ranked 5,108th out of 14,666 executives tracked by ExecPay. In other words, Tomsicek earned more than 65.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,108 out of 14,666 | 65th |
Division Manufacturing | 1,815 out of 5,768 | 69th |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 252 out of 856 | 71st |
Industry group Surgical, Medical, And Dental Instruments And Supplies | 130 out of 528 | 75th |
Industry Surgical and Medical Instruments and Apparatus | 79 out of 333 | 76th |
Source: SEC filing on June 23, 2017.
Tomsicek's colleagues
We found four more compensation records of executives who worked with Michael J. Tomsicek at ABIOMED in 2017.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019
ABIOMED CEO Michael Minogue's 2018 pay slips 16% to $10M
June 22, 2018